BCL2L1

BCL2 Like 1

Score: 0.675 Price: $0.68 High Druggability Status: active Wiki: BCL2L1

🧠 Neurodegeneration

HYPOTHESES

1

PAPERS

31

KG EDGES

1011

DEBATES

1

3D Protein Structure

🧬 BCL2L1 — PDB 1PQ1 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

High

Score: 0.80

Clinical Stage

Approved

Target Class

Signaling Protein

Safety

0.40

Druggability Analysis

Drug Development0.75

Structural Tractability0.95

Target Class0.50

Safety Profile0.40

Key Metrics

PDB Structures:

105

Known Drugs:

2

Approved:

1

In Clinical Trials:

0

Drug Pipeline (2 compounds)

1 Approved · 1 Preclinical

Druggability Rationale: BCL2L1 is highly druggable (0.80 score) due to its well-characterized hydrophobic BH3-binding groove, extensive structural data (105 PDB structures at 1.3 Å resolution), and validated clinical precedent with approved drug Venetoclax. The signaling protein class and proven small-molecule inhibitor mechanism demonstrate clear feasibility for therapeutic modulation.

Mechanism: Small molecule inhibitor of anti-apoptotic protein function

Drug Pipeline (2 compounds)

1 Approved · 1 Preclinical

Known Drugs:

Navitoclax (investigational) — Cancer

Venetoclax (approved) — Cancer

Structural Data:

PDB (105) ✓AlphaFold ✓Cryo-EM —

1MAZ 1YSG 1YSI 1YSN 2B48+100 more

UniProt: Q07817

🧬 3D Protein Structure

🧬 BCL2L1 — PDB 1PQ1 Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

BCL2L1 selectivity versus other anti-apoptotic BCL2 family members (BCL2, MCL1, BCL2L2) is critical, as off-target engagement risks unintended apoptosis or toxicity in healthy tissues. Neuroprotective applications require improved selectivity compared to existing cancer-focused inhibitors to minimize peripheral side effects.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (8)

Relevant trials from ClinicalTrials.gov

Active

1

Completed

7

Total Enrollment

860

By Phase

NA: 5 · PHASE1: 1 · PHASE2: 1 · Unknown: 1

Anger Control Training for Youth With Tourette Syndrome Completed

NA NCT00486551 n=26

Tourette Syndrome, Chronic Tic Disorder, Oppositional Defiant Disorder

Interventions: Anger control training

Sponsor: Yale University | Started: 2001-08

Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease Recruiting

NA NCT06909045 n=130

Deep Brain Stimulation, Parkinson Disease

Interventions: Adaptive DBS, Continue DBS

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC | Started: 2026-01-27

Expiratory Muscle Training in Patients With Parkinson's Disease Completed

PHASE1 NCT00843739 n=90

Parkinson's Disease

Interventions: EMST - Active Treatment, sham EMST

Sponsor: University of Florida | Started: 2004-01

Study of the Follow-up of Stroke Treated With Anticoagulants Completed

Unknown NCT03292575 n=441

Stroke

Interventions: Anticoagulants

Sponsor: Centre Hospitalier Universitaire Dijon | Started: 2016-01

Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease Completed

NA NCT01924312 n=80

Cerebrovascular Disease, Mild Cognitive Impairment

Interventions: Heart Health Intervention

Sponsor: Gregory Jicha, 323-5550 | Started: 2013-05

Effects of Modern Board Games on Well Being in Older Adults Completed

NA NCT06306365 n=35

Executive Functions

Interventions: Modern board game-based learning

Sponsor: European University Miguel de Cervantes | Started: 2024-02-07

Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol Completed

NA NCT02260167 n=25

Alzheimer's Disease, Dementia

Interventions: A mix of natural treatments and medicati

Sponsor: Practitioners Alliance Network | Started: 2014-09

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) Completed

PHASE2 NCT03987295 n=33

Frontotemporal Dementia

Interventions: AL001

Sponsor: Alector Inc. | Started: 2019-09-27

Linked Hypotheses (1)

Senescent Microglia Resolution via Maresins-Senolytics Combination0.784

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Knowledge Graph (20)

activates (1)

associated with (12)

BCL2L1→neurodegenerationULK1→BCL2L1BCL2→BCL2L1RAB9A→BCL2L1BCL2L1→GLA

▸ Show 7 more

BCL2L1→GABARAPBCL2L1→PSEN2BCL2L1→CTSDBCL2L1→FYCO1BCL2L1→LAMP2BCL2L1→SOX9BCL2L1→WDR45

co discussed (6)

ALOX15→BCL2L1BCL2L1→TFRCBCL2L1→GPR37BCL2L1→CMKLR1BCL2L1→ALOX12

▸ Show 1 more

expressed in (1)

Debate History (1)

Should BCL2L1 (BCL2 Like 1) be prioritized as a therapeutic target for neurodege2026-04-21